Clinical Characteristic | Number (%) |
---|---|
Sex | |
Male | 74 (90) |
Female | 8 (10) |
Prior AIDS-defining illness | |
No | 68 (83) |
Yes | 14 (17) |
On antiretrovirals prior to ARL diagnosis | |
No | 31 (38) |
Yes | 51 (62) |
HIV-1 RNA viral load <50 copies/mL at the time of diagnosisb | |
No | 62 (76) |
Yes | 20 (28) |
International Prognostic Index risk groupc | |
High | 21 (26) |
High/intermediate | 22 (28) |
Low | 19 (24) |
Low/intermediate | 18 (22) |
ECOG performance status | |
0 | 5 (6) |
1 | 39 (48) |
2 | 22 (27) |
3 | 9 (11) |
4 | 7 (8) |
Histology | |
Burkitt | 11 (13) |
DLBCL | 65 (79) |
Other | 5 (8) |
Meningeal enhancement on CT | |
No | 79 (97) |
Yes | 3 (3) |
Parenchymal lesion on CT brain | |
No | 75 (91) |
Yes | 7 (9) |
Raised CSF protein | |
No | 36 (44) |
Yes | 43 (46) |
Meningeal disease at diagnosis | |
No | 65 (79) |
Yes | 17 (21) |
Note:—DLBLC indicates diffuse large B-cell lymphoma; RNA, ribonucleic acid.
a CD4 subset analysis was performed using whole blood stained with murine antihuman monoclonal antibodies to CD4 (T helper cells, TetraOne; Beckman Coulter, High Wycombe, UK) and was evaluated on an Epics XL-MCL (Beckman Coulter) multiparametric 4-color flow cytometer. There were no missing data.
b Plasma viral loads (Quantiplex HIV RNA 3.0; Chiron, Halstead, UK) were recorded since 1998 with a lower limit of detection of 50 copies/mL.
c The International Prognostic Index was defined according to well-known established criteria.12